Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

Completed · Phase 4

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to evaluate the impact of rapid infusion rituximab on the incidence of infusion-related reactions in patients with Autoimmune Diseases.

Key facts

Study ID

NCT02040116

Run by

Wake Forest University Health Sciences

People needed

19

Starts

2013-02-01

Expected to finish

2014-08-01

Last updated by the study team

2018-09-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Autoimmune patient at Wake Forest Baptist Health that is eligible for rituximab therapy
• Tolerate the standard infusion rituximab with ≤ grade 2 hypersensitivity reaction
• Consent to participate in the rapid infusion study
• Age ≥ 18 years ≤ 80 years

You may not qualify if…

• Tolerate the standard infusion rituximab with ≥ grade 3 hypersensitivity reaction
• Neurocognitive impairment (i.e. dementia, Alzheimers, et al)

Where it is running

• Wake Forest Baptist Medical Center — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.